The Synergism of Human Lactobacillaceae and Inulin Decrease Hyperglycemia via Regulating the Composition of Gut Microbiota and Metabolic Profiles in db/db Mice

Peifan Li, Tong Tong, Yusong Wu, Xin Zhou, Michael Zhang, Jia Liu, Yongxin She, Zuming Li, Yongli LiJournal of Microbiology and Biotechnology 2023 · DOI

Abstract

This study investigates the combined effects of human-derived Limosilactobacillus fermentum and Lactiplantibacillus plantarum with the prebiotic inulin (LI) on type 2 diabetes mellitus (T2DM) in db/db mice. Over a 12-week period, the LI intervention significantly reduced fasting blood glucose levels and improved colon tissue integrity compared to diabetic controls. Multi-omics analysis revealed that LI treatment reshaped the gut microbiota—decreasing pathogens like Corynebacterium and Proteus while restoring beneficial genera—and normalized metabolic pathways related to tryptophan and linoleic acid. These findings suggest that synbiotic interventions can effectively manage T2DM by modulating the gut-metabolism axis.

Introduction

Type 2 Diabetes Mellitus (T2DM) is a global health challenge characterized by chronic hyperglycemia and metabolic dysfunction. Recent research highlights the critical role of gut dysbiosis—an imbalance in intestinal microbial communities—in the progression of T2DM. While probiotics and prebiotics have been studied individually, their synergistic "synbiotic" potential offers a more robust approach to restoring intestinal homeostasis. This study explores how a specific combination of human-derived Lactobacillaceae and inulin can mitigate diabetic symptoms by rewiring the gut's microbial and metabolic landscape.

Methods and Experimental Design

The researchers utilized db/db mice, a well-established genetic model for T2DM. The mice were categorized into four groups: a normal control (NC), a diabetic model control (MC), a probiotic cocktail group (L), and a probiotics plus 5% inulin group (LI). The 12-week intervention was evaluated using a multi-omics framework including 16S rRNA sequencing for microbiota profiling and untargeted metabolomics for cecal metabolite identification.

Comprehensive gut microbiota analysis including diversity indices, OTU distribution, and community structure (PCoA/NMDS).

Key Results

Improved Glucose Regulation and Intestinal Health

The most prominent physiological outcome was the significant reduction in fasting blood glucose (FBG) in the LI group compared to the MC group. Furthermore, the synbiotic treatment preserved the structural integrity of the colon, preventing the thinning of the intestinal wall and reducing inflammatory infiltration typically seen in diabetic models.

Fasting blood glucose levels (A) and colon histopathology (B) demonstrating the therapeutic effect of the LI treatment.

Reshaping the Gut Microbiota

The LI intervention effectively suppressed opportunistic pathogens such as Corynebacterium and Proteus. Simultaneously, it restored key beneficial genera, including Lachnospiraceae and Lachnoclostridium. Diversity analysis and community clustering confirmed that the LI treatment shifted the diabetic microbiome toward a state more similar to the healthy control.

Metabolic Pathway Normalization

The study identified 138 differential metabolites, with LI treatment reversing the abnormal levels of L-phenylalanine and L-tryptophan found in diabetic mice. Specifically, LI normalized the "serotonergic synapse" pathway and restored levels of 13(S)-HpODE, a signaling molecule involved in linoleic acid metabolism. Additionally, LI significantly boosted levels of short-chain fatty acids (SCFAs), which are vital for improving insulin sensitivity.

Discussion and Future Directions

The synergistic effect of Lactobacillaceae and inulin proves more effective than probiotics alone, suggesting that the prebiotic fiber provides a necessary substrate for the beneficial bacteria to thrive. While these results are promising, the study's reliance on a mouse model necessitates future clinical trials. Further research using fecal microbiota transplantation (FMT) is also required to establish direct causality between specific microbes and metabolic improvements. These results provide a foundation for developing synbiotic-based therapies for T2DM management.

Summary updated

Abstract

This study aimed to evaluate the effects of <i>Limosilactobacillus fermentum</i> and <i>Lactiplantibacillus plantarum</i> isolated from human feces coordinating with inulin on the composition of gut microbiota and metabolic profiles in db/db mice. These supplements were administered to db/db mice for 12 weeks. The results showed that the <i>Lactobacillaceae</i> coordinating with inulin group (LI) exhibited lower fasting blood glucose levels than the model control group (MC). Additionally, LI was found to enhance colon tissue and increase the levels of short-chain fatty acids. 16S rRNA sequencing revealed that the abundance of <i>Corynebacterium</i> and <i>Proteus</i>, which were significantly increased in the MC group compared with NC group, were significantly decreased by the treatment of LI that also restored the key genera of the <i>Lachnospiraceae</i>_NK4A136_group, <i>Lachnoclostridium</i>, <i>Ruminococcus_gnavus_group</i>, <i>Desulfovibrio</i>, and <i>Lachnospiraceae_UCG-006</i>. Untargeted metabolomics analysis showed that lotaustralin, 5-hydroxyindoleacetic acid, and 13(S)-HpODE were increased while L-phenylalanine and L-tryptophan were decreased in the MC group compared with the NC group. However, the intervention of LI reversed the levels of these metabolites in the intestine. Correlation analysis revealed that <i>Lachnoclostridium</i> and <i>Ruminococcus_gnavus</i>_group were negatively correlated with 5-hydroxyindoleacetic acid and 13(S)-HpODE, but positively correlated with L-tryptophan. 13(S)-HpODE was involved in the "linoleic acid metabolism". L-tryptophan and 5-hydroxyindoleacetic acid were involved in "tryptophan metabolism" and "serotonergic synapse". These findings suggest that LI may alleviate type 2 diabetes symptoms by modulating the abundance of <i>Ruminococcus_gnavus_group</i> and <i>Lachnoclostridium</i> to regulate the pathways of "linoleic acid metabolism", "serotonergic synapse", and" tryptophan metabolism". Our results provide new insights into prevention and treatment of type 2 diabetes.
BibTeX
@article{li2023synergism,
  author = {Peifan Li and Tong Tong and Yusong Wu and Xin Zhou and Michael Zhang and Jia Liu and Yongxin She and Zuming Li and Yongli Li},
  title = {{The Synergism of Human <i>Lactobacillaceae</i> and Inulin Decrease Hyperglycemia via Regulating the Composition of Gut Microbiota and Metabolic Profiles in db/db Mice}},
  journal = {Journal of Microbiology and Biotechnology},
  year = {2023},
  doi = {10.4014/jmb.2304.04039},
}
Figure